FOR IMMEDIATE RELEASE

18 August, 2009

BIOQUELL PLC

2009 interim results

BIOQUELL PLC (“BIOQUELL”) (LSE symbol: BQE), a leading international provider of specialist bio-decontamination technologies and testing / compliance services, announces its interim results for the six months ended 30 June 2009.  The highlights are:

Financial

• Group revenues of £19.8m (2008: £17.2m) - increase of 15%
• 21% increase in Bio-decontamination division revenues to £14.3m (2008: £11.8m)
• Profit before tax of £2.8m (2008: £2.4m) - increase of 17%
• Earnings per share of 4.9p (2008: 4.4p) - increase of 11%
• Net cash £4.8m (2008: £4.1m) - comprising cash of £6.5m and debt of £1.7m

Activities

• Increase in revenues primarily due to sales of BIOQUELL’s unique hydrogen peroxide vapour (“HPV”) bio-decontamination equipment and services across all three of the Group’s core sectors: healthcare, life sciences and defence
• Positive report published jointly by the UK Department of Health and NHS Purchasing and Supply Agency relating to the use of BIOQUELL’s HPV technology to eradicate “superbugs” in NHS hospitals: “in total 2,093 rooms were disinfected….the BIOQUELL system did not cause undue disruption and was very popular – 99% of staff would recommend it” Click here... for full report.
• Further ‘proactive’ bio-decontamination service contracts sold to US hospitals – comprising BIOQUELL technicians and proprietary BIOQUELL equipment located full time at the hospital
• Increased HPV bio-decontamination equipment and RBDS service sold to a broad range of life science clients – with notable demand from vaccine and biologics companies
• Good progress on the US Department of Defense’s JMDS contract – which uses BIOQUELL’s HPV technology to inactivate biological and chemical weapons
• Increasing momentum at TRaC – the Group’s specialist Testing, Regulatory and Compliance business

Commenting on the interim results, Nigel Keen, Chairman of BIOQUELL PLC said:

“BIOQUELL continues to invest strongly in promoting the use of its unique hydrogen peroxide bio-decontamination technology in the healthcare sector – and we are delighted to see the positive feedback from the Department of Health’s Showcase Hospital Programme report which highlights the applicability of BIOQUELL’s technology in hospitals”

“It is extremely encouraging to see the Group showing strong growth across its three core sectors - life sciences, healthcare and defence - despite the difficult global economic climate. Against this backdrop – which is supported by the Group’s substantial net cash position – we look forward to reporting further good progress in the second half of the year”

To view the full results, Click here...

Enquiries:

Nigel Keen BIOQUELL PLC 01264 835 900
Nick Adams
Mark Bodeker